Dianthus Platform: Screening for Modulators of SIK3
Salt-inducible kinases (SIKs) have recently emerged as key regulators of oncogenesis, inflammation, and immune responses, making these enzymes an important drug target. The isoform SIK3 is a novel regulator of tumor-intrinsic resistance to cytotoxic T cell attack. To support the discovery of novel SIK3 modulators, WuXi AppTec offers an integrated platform of ready-to-go biophysical assays and Dianthus, a plate-based, affinity screening platform providing high quality data.

Dianthus SIK3
Related Content
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...
VIEW RESOURCEGouty arthritis is a common, painful inflammatory condition characterized by the deposition of monosodium urate (MSU) crystals in joints. This...
VIEW RESOURCE
